Kết quả của hóa xạ trị tiền phẫu ung thư thực quản giai đoạn II, III tại Bệnh viện Ung bướu Thành phố Hồ Chí Minh

Abstract

Objective: To describe some clinical characteristics and evaluate results of preoperative chemoradiotherapy in patients with resectable stage II, III esophageal cancer at Ho Chi Minh City Oncology Hospital. Subject and method: A case series of 27 patients with resectable stage II, III esophageal cancer who received neoadjuvant chemoradiotherapy with a weekly regimen of paclitaxel/carboplatin (paclitaxel 50mg/m², carboplatin AUC 2) for 5 weeks and concurrent radiotherapy (41.4Gy in 23 fractions), followed by esophagectomy. Result: The mean age was 57 years old, the percentage of male was 100%. The most common symptom was dysphagia (88.9%). Weight loss was observed in 66.7% of patients. The mean length of tumor was 5.5 ± 2cm. The majority of patients were in stage III (66.7%). After neoadjuvant chemoradiotherapy, the overall clinical response rate reached 92.6%. The complete response according to RECIST 1.1 criteria was 18.5%. There were 74.1% of patients undergoing esophagectomy. The pathologic complete response (pCR) rate was 40% and R0 resection rate was 95%. The complete tumor regression was achieved in 50% of patients. The common toxic effects of neoadjuvant chemoradiotherapy are leukopenia, thrombocytopenia, esophagitis, radiation pneumonitis. Conclusion: Neoadjuvant chemoradiotherapy is an effective and well-tolerated treatment with negligible adverse-event rates for patients with resectable stage II, III esophageal cancer.